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(ELIOT). Both APBI and IORT patients have been followed 
prospectively with the same QoL questionnaires: 1 week, 3 
months, 6 months and yearly after breast conserving 
treatment.  
Results: In November 2014 the IORT part of the study 
accrued 192 patients; the APBI part 86 patients. The overall 
response for the QoL questionnaires was 82–98% at the 
different time points. 
There is a non-significant (ns) difference in pain score (VAS 1-
10) 1 week after surgery in favor of APBI patients. After 
completion of radiotherapy this difference is significant in 
favor of the APBI patients, maybe due to wound healing in 
the 4 to 5 weeks after breast conserving surgery. In time this 
difference changes, resulting in a significant difference in 
favor of IORT at 3 and 6 months. 
For fatigue (EORTC C30) the results are comparable; more 
patients are tired (ns) just after surgery for IORT, but again 
less tired at 6 and 12 months. In the explorative analysis, so 
far, co morbidity, not age, seems to influence fatigue. 
Correcting for co morbidity fatigue at 6 and 12 months is 
significant better for IORT. 
 
Mean QoL  
score 
1 week  
after surg 
IORT/APBI 
After RT 
APBI 
3 month 
IORT/APBI 
6 month 
IORT/APBI 
1 year 
IORT/APBI 
IORT pain 2.8   1.9 * 1.8 *  1.7 
APBI pain 2.5  2.2 * 2.6 2.5 2.2 
IORT fatigue 35  25 23** 21** 
APBI fatigue 28 30 26 26  26  
* significant less pain (VAS 1-10);  
** significant less fatigue, when corrected for age and comorbidity (EORTC C30) 
 
Conclusions: This preliminary analysis shows a significant 
better result for pain and fatigue for IORT compared to 
external beam APBI in the first year of follow up. An update 
of the results will be presented including the analysis of the 
confounding factors. 
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Purpose/Objective: To evaluate retrospectively survival and 
local control rates (LCR) of triple negative breast cancer 
(TNBC) subtypes classified in five marker negative (5-NP) and 
core basal (CB) after breast conserving surgery (BCS) and 
intraoperative radiotherapy with electrons (IOERT). 
Materials and Methods: 71 TNBC patients were enrolled. All 
patients were treated with BCS, axillary lymph node 
dissection and received IOERT with a median dose maximum 
of 9.6 Gy as anticipated tumorbed boost, which was followed 
by whole breast irradiation (WBI) to median total doses of 54 
Gy (range 51-57.6) in normofractionation (1.6 - 1.85 Gy 
(5Fx/week). Chemotherapy was applied neoadjuvant (12%), 
adjuvant (75%) or in combination (7%). 
Results: After a median follow-up of 97 months (range 4-170) 
5 ipsilateral breast tumor recurrences (IBTR) were detected 
(7.0%). 8-year actuarial rates of all TNBC patients for local 
control (LCR), metastases free survival (FFM), disease 
specific survival (DSS), and overall survival (OS) amount 91%, 
75%, 80%, and 69%, respectively. Subgroupanalyses revealed a 
trend of inferior outcome for CB in DSS if compared to 5-NP 
(5-NP:83% vs CB:54% for G1/G2, p=0.27, 5-NP:90% vs CB: 79% 
for G3 tumors, p=0.30 and 5-NP G3: 90% vs CB G1/2: 54%, 
p=0.03), whereas LCR seemed to be negative influenced by 
tumor grading G3 (G1/2 (CB and 5-NP):100% vs G3: 88% (5-
NP) and 90% (CB), p=0.65 and 0.82), both without statistical 
significance. 
Conclusions: IOERT as boost modality during BCT of TNBC, 
provides acceptable LCR. CB-subtype and tumorgrading G3 
are negative predictors for survival and LCR, respectively.  
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Purpose/Objective: The aim of the study was to report 
effectiveness, quality of life, toxicity, cosmetic outcomes 
and physical parametres of intraoperative radiotherapy 
(IORT) given as a boost during breast conserving surgery (BCS) 
followed by adjuvant whole breast radiotherapy (WBI).  
Materials and Methods: Between 2008 and 2011 in 150 breast 
cancers patients treated in our centre intraoperative 
radiotherapy as a tumor bed boost was applied using mobile 
electron accelerator Mobetron 1000 (IntraOp Medical, Inc.). 
IORT boost (10 Gy) was followed by 50 Gy whole-breast 
external beam radiotherapy (EBRT). Chemotherapy, if 
indicated, was given before EBRT. The observation period 
was 1,5-5,5 years. 
Clinical outcomes was assessed by physical examination, 
photos of the breast with Harris-Limbergen scale, EORTC 
questionnaires (QLQ-C30 and QLQ-BR23), analysis of acute 
and late toxicity (CTCAE v 3.0 and LENT-SOMA scales), 
mammography, ultrasounds and chest X-ray. 
Results: There was no local recurrences. Acute skin reactions 
in grade 1 and 2 were observed in 31% of pts in 1 month post 
RT and 9% in 6 months post RT, with no acute and late 
toxicities in grade 3 and 4. 
The cosmetic outcome was good to excellent in 81,5% of pts 
1 month post RT and 87% 3 years post RT. 
Pain in breast was observed in 53 % pts 1 month post RT and 
21% 6 months posr RT, hyperesthesia of the skin in 17,0 % pts. 
The data was tested with Mantel-Haenschel test. There was 
no statistical significance.  
The late toxicity was evaluated one year after radiation 
therapy. The edema of breast was reported by 18 % of pts.  
The telangiectasia of breast skin has occurred in 25 % of pts. 
Retraction of the breast occurred in 39% of pts. Fibrosis was 
detected in 60% of patients. 
There was no statistical significance change in quality of life 
in any follow-up period based on Friedman test analysis 
(p=0,2143). 
Patients were treated using all available electron beam 
energies: 6 MeV energy was used in 58% cases but also 9 MeV, 
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4 MeV and 12 MeV (20%, 14% and 6% cases respectively) were 
used. In 54% cases applicator size was 5 cm in diameter. The 
smallest was 4 cm (15%) and the largest 7 cm (used only in 5% 
cases). Treatment applicators with 0°, 15° and 30° beveled 
tips were used (32%, 41% and 26% cases respectively). In 60% 
cases no bolus was needed; 0.5 cm bolus was used in 44 cases 
(29%). In all treatment procedures aluminium-lead shielding 
plates were used, 85% of which were 0.5 cm thick. The mean 
thickness of irradiated breast gland was 2.1 cm between 0.8 
cm and 3 cm. PTV volume (volume of tissue encompassed by 
the 90% isodose line) was rather small, with average volume 
of 42.50 cc ranging from 15.00 cc to 92.10 cc. 
Conclusions: Intraoperative radiotherapy is proved to be 
effective, tolerable and perspective treatment procedure. 
The external beam course afterwards was shortened by 1 
week.  
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Purpose/Objective: Long term follow-up (f/u) of patients 
(pts) undergoing accelerated partial breast irradiation (APBI) 
with single-fraction (SF) intraoperative radiotherapy (IORT) 
following breast conserving (BC) surgery is limited. We report 
our institutional experience with SF IORT in early stage 
breast cancer with respect to local control and toxicity.  
Materials and Methods: Records were reviewed for 64 
consecutive pts who received SF IORT from 2002 to 2014 at 
our institution. Of these, 47 pts were prospectively enrolled 
in an institutional IRB-approved phase I-II study between 2002 
and 2008. Eligible pts were ≥40 years with stage 0, I or II 
breast cancer measuring ≤2.5 cm without nodal involvement 
and were all screened with breast MRI for multifocal (MF) or 
multicentric (MC) disease (both exclusion criteria) (EC). 8 of 
the 47 pts did not fully meet eligibility criteria and declined 
additional surgery or radiation. The remaining 17 patients 
were treated per protocol guidelines between 2009 and 2014. 
IORT was delivered using either a 200 kV orthovoltage source 
or electrons to 15-21 Gy prescribed to the 90% isodose line. 
Results: The median age at treatment was 61 years (range: 
40-84 years). Median f/u time was 88 months (range 1 – 144 
months). Two pts had an ipsilateral breast tumor recurrence 
(IBTR), with one not meeting EC. A third patient with EIC and 
nodal micrometastasis later developed an axillary 
recurrence. All 3 patients had declined further surgery, 
radiation and/or systemic therapy. Overall, 52 of 64 pts (81%) 
received adjuvant systemic therapy consisting of endocrine 
therapy (n=49), chemotherapy (n=5) and/or trastuzumab 
(n=1). For patients who met original protocol guidelines, the 
IBTR rate was 1.6% at 6 years of f/u. On univariate analysis, 
the following factors emerged as significant predictors of 
IBTR: age <50 years (p<0.001), pathologic nodal involvement 
(p<0.001) and lack of any adjuvant systemic therapy 
(p=0.001). There were 2 cases of isolated distant relapses, 
which occurred in patients who had also declined adjuvant 
systemic therapy. Lack of systemic therapy was the only 
significant predictor of distant relapse (p=0.01). All 64 
patients tolerated IORT well with no evidence of grade III or 
higher toxicity. 
Conclusions: APBI using IORT is an inherently desirable 
option for BC therapy in appropriately selected pts. Our 
group has an IBTR rate of 1.6% at 7 years of f/u. We conclude 
that adherence to appropriate clinical guidelines for patient 
selection and strongly advising adherence to 
recommendations for additional surgery, radiation and 
systemic therapy are critical for successful use of APBI using 
SF IORT.  
   
 
Poster Discussion: IORT in breast cancer: Where do we 
stand?  
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Purpose/Objective: In selected patients, partial breast 
irradiation (PBI) could be a good option for delivering 
radiation therapy. Brachytherapy, conformal external 
radiation therapy (EBRT) and intraoperative radiation therapy 
(IORT) are the most common therapies as PBI. Using an 
Intrabeam® device as IORT has been considered expensive 
due to the initial cost of the equipment. 
The purpose of this study is to elucidate the real cost of IORT 
with Intrabeam® in breast cancer, comparing with 
conventional EBRT. 
Materials and Methods: Between Jan-2013 and Nov-2014, 75 
breast cancer patients were treated with IORT during 
conserving surgery in our institution, delivering a dose of 20 
Gy, with treating times adjusted to applicator diameter. 
Costs were estimated with time of surgery theatre 
occupation, radiation oncologist, physicist and technician, 
fungible material, applicators and total equipment cost 
distributed proportionately among patients. For EBRT costs 
calculations, there has been included institutional fares and 
price for distance travelled by patients daily. Also we 
calculated the waiting time that could influence QoL. 
Results: - For the 75 IORT patients, treatment time was 
registered by the device software, with an average of 
24.66min (15.97-49.07min), meaning an added cost of 
327.46€ (212.04-651.6€). Equipment total cost proportion 
was 1600 €/patient. Adding staff time and fungibles, the 
average total cost of the procedure has been 2398.45€ 
(2283.03-2722.6€). For the whole series, the total estimated 
cost has been 201123.75€. 
- The average 75 EBRT cost per patient was 3980.43€, with a 
total cost of 298532.25€ for the 75 patients. Considering daily 
patient routes twice a day, 25 days, total cost will be 
increased to 299376.45€, being a more realistic approach. 
- For the 75 patients treated with Intrabeam®, 98252.70€ 
have been saved, comparing with equivalent EBRT.  
Investigating daily waiting time during EBRT, we have 
compared the difference between the daily treatment 
appointment time and the real treatment time in 12 random 
patients of the previous year. We found an average daily 
delay of 15.9min/patient, that means a total waste of 6h and 
37min/patient for the whole treatment and a total of 497h 
for the 75 patients. As personal cost, the whole group had 
employed more than 20 days waiting to be treated with 
EBRT. 
Conclusions: Despite of the apparent high cost of equipment 
needed, IORT with an Intrabeam® device presents an 
